BidaskClub lowered shares of Epizyme (NASDAQ:EPZM) from a hold rating to a sell rating in a research report released on Thursday, September 13th.
Other equities analysts have also recently issued research reports about the company. Wedbush lifted their target price on Epizyme from $20.00 to $25.00 in a research note on Friday, May 18th. Zacks Investment Research raised Epizyme from a hold rating to a buy rating and set a $14.00 target price on the stock in a research note on Friday, July 6th. HC Wainwright reaffirmed a buy rating and set a $25.00 target price on shares of Epizyme in a research note on Monday, May 21st. Cann reaffirmed a buy rating and set a $27.00 target price on shares of Epizyme in a research note on Thursday, August 2nd. Finally, ValuEngine raised Epizyme from a sell rating to a hold rating in a research note on Thursday, July 26th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $21.00.
NASDAQ:EPZM traded up $0.24 on Thursday, hitting $9.24. 810,600 shares of the company’s stock traded hands, compared to its average volume of 468,268. Epizyme has a 1 year low of $8.61 and a 1 year high of $21.40. The stock has a market cap of $736.73 million, a PE ratio of -4.30 and a beta of 1.65.
Epizyme (NASDAQ:EPZM) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.53) by $0.11. The business had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $0.54 million. During the same period last year, the firm earned ($0.48) EPS. The company’s revenue was up 20.0% compared to the same quarter last year. Sell-side analysts forecast that Epizyme will post -2.14 EPS for the current year.
In other news, Director David M. Mott purchased 416,667 shares of the stock in a transaction that occurred on Friday, October 5th. The stock was acquired at an average price of $9.00 per share, with a total value of $3,750,003.00. Following the purchase, the director now owns 12,088 shares in the company, valued at approximately $108,792. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 21.50% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Northern Trust Corp grew its stake in shares of Epizyme by 0.6% in the 1st quarter. Northern Trust Corp now owns 580,898 shares of the biopharmaceutical company’s stock valued at $10,311,000 after buying an additional 3,538 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Epizyme by 9.4% in the 1st quarter. Rhumbline Advisers now owns 48,210 shares of the biopharmaceutical company’s stock valued at $856,000 after buying an additional 4,130 shares in the last quarter. BB&T Securities LLC boosted its position in Epizyme by 45.5% during the second quarter. BB&T Securities LLC now owns 16,000 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 5,000 shares during the period. New York State Common Retirement Fund boosted its position in Epizyme by 11.8% during the first quarter. New York State Common Retirement Fund now owns 52,100 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 5,500 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Epizyme by 2.7% during the second quarter. Bank of New York Mellon Corp now owns 225,764 shares of the biopharmaceutical company’s stock worth $3,058,000 after purchasing an additional 6,012 shares during the period. 85.06% of the stock is owned by institutional investors and hedge funds.
Epizyme Company Profile
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Read More: What Does Beta Mean In Stock Selection
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.